Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update Cyclacel Pharmaceuticals (NASDAQ: CYCC) reported its Q2 2025 financial results and significant corporate developments. The company entered a major share exchange agreement with FITTERS Diversified Berhad, where Fitters Parent will exchange 100% of FITTERS Sdn. Bhd. for approximately 19.99% of Cyclacel's common stock, plus $1,000,000 in cash consideration.Key financial highlights include cash position of $4.3 million as of June 30, 2025, up from $3.2 million in December 2024. The company raised $3 million through Series F Convertible Preferred Stock offering and implemented a 1-for-15 reverse stock split to meet Nasdaq requirements. Q2 2025 saw reduced R&D expenses of $0.1 million (vs $2.0 million in Q2 2024) and lower G&A expenses of $1.2 million (vs $1.6 million in Q2 2024), resulting in a net loss of $1.3 million.

#CYCC #CYCCP Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

www.stocktitan.net/news/CYCC/cyclacel-pharm...

Breakthrough: Novel Drug Plogosertib Effectively Targets Aggressive Biliary Cancer, Study Reveals Key Biomarker Preclinical data reveals plogosertib's effectiveness against biliary tract cancer, with BUBR1 identified as key biomarker. See combination therapy results.

#CYCC #CYCCP CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

www.stocktitan.net/news/CYCC/cyclacel-pharm...

CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY Cyclacel Pharmaceuticals (NASDAQ: CYCC) has issued a statement addressing recent unusual stock price movements. The company confirmed that there are no material developments or changes to its operating or financial condition that would explain the significant volume and price fluctuations observed on July 15, 2025.The biopharmaceutical company emphasized that aside from its previously announced amendment to the Exchange Agreement with FITTERS Diversified Berhad on July 7, 2025, there have been no material adverse changes to its business operations, strategy, or prospects.

#CYCC #CYCCP CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY

www.stocktitan.net/news/CYCC/cyclacel-pharm...

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT Cyclacel Pharmaceuticals (NASDAQ: CYCC) has amended its Exchange Agreement with FITTERS Diversified Berhad. The amended agreement includes a new cash consideration of $1 million in addition to the previously agreed stock exchange and extends the final date to September 30, 2025.Under the Transaction, Cyclacel will acquire all ordinary shares of Fitters Sdn. Bhd., making it a wholly-owned subsidiary, in exchange for Cyclacel common stock representing 19.99% of outstanding shares. The deal requires approval from both companies' stockholders and has received unanimous board approval from all parties involved.

#CYCC #CYCCP CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

www.stocktitan.net/news/CYCC/cyclacel-pharm...

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER Cyclacel Pharmaceuticals (NASDAQ: CYCC) announced the publication of preclinical data demonstrating the effectiveness of their drug plogosertib in treating fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer affecting young people with no approved treatments.The study, published in the journal Gut, revealed that FLC cells are highly sensitive to PLK1 inhibition by plogosertib. The research showed that the DNAJ-PKAc fusion oncoprotein, which drives FLC progression, interacts with PLK1 at the centrosome. Notably, plogosertib demonstrated significant reduction in FLC growth while sparing normal liver cells in both in vitro and in vivo models.

#CYCC #CYCCP CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

www.stocktitan.net/news/CYCC/cyclacel-pharm...

Cyclacel Announces Major Share Restructuring: 23.7M Shares Consolidating to 1.58M Cyclacel's reverse stock split reduces 23.7M shares to 1.58M. Learn how this 1:15 ratio affects your holdings and trading implications. Get full details.

#CYCC #CYCCP Cyclacel Pharmaceuticals Announces Stock Split

www.stocktitan.net/news/CYCC/cyclacel-pharm...

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock Cyclacel Pharmaceuticals (NASDAQ: CYCC) has secured $3 million in gross proceeds through a private placement of convertible Series F Preferred Stock to accredited investors. The company issued three series of warrants (A, B, and C) to purchase 3,270,000 shares each of common stock at exercise prices of $0.51, $0.60, and $0.68 respectively, with a 5-year expiration. Each preferred share is convertible into 3.27 common shares, subject to stockholder approval. The financing, combined with existing cash, is expected to extend Cyclacel's runway into Q3 2025. The proceeds will be used for working capital and general corporate purposes. The securities were issued under Regulation S and have not been registered under the Securities Act of 1933.

#CYCC #CYCCP Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

www.stocktitan.net/news/CYCC/cyclacel-pharm...

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT Cyclacel Pharmaceuticals (NASDAQ: CYCC) has announced a 1-for-16 reverse stock split effective May 12, 2025. The company's common stock will continue trading on the Nasdaq Capital Market under the symbol "CYCC" with a new CUSIP number 23254L884.Following the split, every 16 shares will automatically convert into one share, with fractional shares being rounded up or down. The pre-split share count of 356,357,531 will be reduced to 22,272,346 post-split. The reverse split was approved by both the board of directors and stockholders, and will not alter shareholders' percentage ownership in the company, except for minor adjustments due to fractional shares.

#CYCC #CYCCP CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

www.stocktitan.net/news/CYCC/cyclacel-pharm...

Cyclacel Slashes Net Loss in Half, Streamlines to Focus on Promising Cancer Drug Cyclacel reduces 2024 net loss to $11.2M, cuts R&D spend by 65% while advancing plogosertib cancer drug development. Strategic pivot promises improved efficiency.

#CYCC #CYCCP Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

www.stocktitan.net/news/CYCC/cyclacel-pharm...

Cyclacel's Latest $1M Financing Deal Reveals Extended Survival Strategy Through Q3 2025 Strategic private placement provides Cyclacel with working capital boost and extends operations. Key details of convertible preferred stock offering revealed. Full analysis inside.

#CYCC #CYCCP Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

www.stocktitan.net/news/CYCC/cyclacel-pharm...

Cyclacel Pharmaceuticals Secures $3.1M Investment, Names David Lazar as Interim CEO Amid Restructuring Cyclacel receives vital funding through preferred stock sale, announces major leadership changes, and initiates cost-reduction plan while facing February 2025 Nasdaq compliance deadline.

#CYCC #CYCCP Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar

www.stocktitan.net/news/CYCC/cyclacel-pharm...

Cyclacel Pharmaceuticals Seeks Urgent Strategic Options Amid Nasdaq Delisting Risk | CYCC Stock News Cyclacel explores strategic alternatives with activist investor amid financial challenges, implementing cost cuts as it faces potential Nasdaq delisting and operational risks.

#CYCC #CYCCP Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

#news #stocks #investing

www.stocktitan.net/news/CYCC/cyclacel-pharm...

#CYCC #CYCCP Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

www.stocktitan.net/news/CYCC/cyclacel-pharm...

#CYCC #CYCCP Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

www.stocktitan.net/news/CYCC/cyclacel-pharm...